#BEGIN_DRUGCARD DB00400

# AHFS_Codes:
Not Available

# ATC_Codes:
D01AA08
D01BA01

# Absorption:
Poorly absorbed from GI ranging from 25 to 70% of an oral dose. Absorption is significantly enhanced by administration with or after a fatty meal.

# Biotransformation:
Primarily hepatic with major metabolites being 6-methyl-griseofulvin and its glucuronide conjugate.

# Brand_Mixtures:
Not Available

# Brand_Names:
Amudane
Biogrisin-fp
Curling factor
Delmofulvina
Fulcin
Fulcine
Fulvican grisactin
Fulvicin
Fulvicin P/G
Fulvicin U/F
Fulvicin-P/G
Fulvicin-U/F
Fulvina
Fulvinil
Fulvistatin
Fungivin
Greosin
Gresfeed
Gricin
Grifulin
Grifulvin
Grifulvin V
Gris-PEG
Grisactin
Grisactin Ultra
Griscofulvin
Grisefuline
Griseo
Griseofulvin forte
Griseofulvin-forte
Griseomix
Grisetin
Grisofulvin
Grisovin
Grisovin FP
Grizeofulvin
Grysio
Guservin
Lamoryl
Likuden
Likunden
Murfulvin
Neo-Fulcin
Neocid
Poncyl
Spirofulvin
Sporostatin
Sporostatin xan
Xuanjing

# CAS_Registry_Number:
126-07-8

# ChEBI_ID:
27779

# Chemical_Formula:
C17H17ClO6

# Chemical_IUPAC_Name:
(2S,6'R)-7-chloro-2',4,6-trimethoxy-6'-methyl-3H-spiro[1-benzofuran-2,1'-cyclohexan]-2'-ene-3,4'-dione

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
332259

# Description:
An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. [PubChem]

# Dosage_Forms:
Suspension	Oral
Tablet	Oral

# Drug_Category:
Antibacterial Agents
Antibiotics, Antifungal

# Drug_Interactions:
Acenocoumarol	Griseofulvin may decrease the anticoagulant effect of acenocoumarol.
Acetylsalicylic acid	Griseofulvin may decrease the efficacy of acetylsalicylic acid.
Amobarbital	The barbiturate, amobarbital, decreases the effect of griseofulvin.
Anisindione	Griseofulvin may decrease the anticoagulant effect of anisindione.
Aprobarbital	The barbiturate, aprobarbital, decreases the effect of griseofulvin.
Butabarbital	The barbiturate, butabarbital, decreases the effect of griseofulvin.
Butalbital	The barbiturate, butalbital, decreases the effect of griseofulvin.
Butethal	The barbiturate, butethal, decreases the effect of griseofulvin.
Chlorotrianisene	The enzyme inducer, griseofulvin, decreases the effect of the hormone agent,  chlorotrianisene.
Clomifene	The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, clomifene.
Conjugated Estrogens	The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, conjugated estrogens.
Cyclosporine	Griseofulvin decreases the effect of cyclosporine
Dicumarol	Griseofulvin may decrease the anticoagulant effect of dicumarol.
Diethylstilbestrol	The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, diethylstilbestrol.
Dihydroquinidine barbiturate	The barbiturate, dihydroquinidine barbiturate, decreases the effect of griseofulvin.
Estradiol	The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, estradiol.
Estriol	The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, estriol.
Estrone	The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, estrone.
Estropipate	The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, estropipate.
Ethinyl Estradiol	This product may cause a slight decrease of contraceptive effect
Heptabarbital	The barbiturate, heptabarbital, decreases the effect of griseofulvin.
Hexobarbital	The barbiturate, hexobarbital, decreases the effect of griseofulvin.
Medroxyprogesterone	The enzyme inducer, griseofulvin, may decrease the effect of the hormone, medroxyprogesterone.
Megestrol	The enzyme inducer, griseofulvin, may decrease the effect of the hormone, megestrol.
Mestranol	This product may cause a slight decrease of contraceptive effect
Methohexital	The barbiturate, methohexital, decreases the effect of griseofulvin.
Methylphenobarbital	The barbiturate, methylphenobarbital, decreases the effect of griseofulvin.
Norethindrone	This product may cause a slight decrease of contraceptive effect
Pentobarbital	The barbiturate, pentobarbital, decreases the effect of griseofulvin.
Phenobarbital	The barbiturate, phenobarbital, decreases the effect of griseofulvin.
Primidone	The barbiturate, primidone, decreases the effect of griseofulvin.
Quinestrol	The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, quinestrol.
Quinidine barbiturate	The barbiturate, quinidine barbiturate, decreases the effect of griseofulvin.
Secobarbital	The barbiturate, secobarbital, decreases the effect of griseofulvin.
Talbutal	The barbiturate, talbutal, decreases the effect of griseofulvin.
Ulipristal 	Concomitant therapy with strong CYP3A4 inducers may decrease plasma concentrations of ulipristal and ultimately its effectiveness. Avoid combination therapy.
Warfarin	Griseofulvin may decrease the anticoagulant effect of warfarin.

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
-4.44

# Experimental_LogP_Hydrophobicity:
2.18

# Experimental_Logs:
-4.61

# Experimental_Water_Solubility:
8.64 mg/L (at 25 °C)

# Food_Interactions:
Avoid alcohol.
Take this medication with a high fat meal, fatty foods increase bioavailability.

# GenBank_ID:
Not Available

# Generic_Name:
Griseofulvin

# HET_ID:
Not Available

# Half_Life:
9-21 hours

# InChI_Identifier:
InChI=1S/C17H17ClO6/c1-8-5-9(19)6-12(23-4)17(8)16(20)13-10(21-2)7-11(22-3)14(18)15(13)24-17/h6-8H,5H2,1-4H3/t8-,17+/m1/s1

# InChI_Key:
InChIKey=DDUHZTYCFQRHIY-RBHXEPJQSA-N

# Indication:
For the treatment of ringworm infections of the skin, hair, and nails, namely: tinea corporis, tinea pedis, tinea cruris, tinea barbae, cradle cap or other conditions caused by <i>Trichophyton</i> or <i>Microsporum</i> fungi.

# KEGG_Compound_ID:
C06686

# KEGG_Drug_ID:
D00209

# LIMS_Drug_ID:
400

# Mechanism_Of_Action:
Griseofulvin is fungistatic, however the exact mechanism by which it inhibits the growth of dermatophytes is not clear. It is thought to inhibit fungal cell mitosis and nuclear acid synthesis. It also binds to and interferes with the function of spindle and cytoplasmic microtubules by binding to alpha and beta tubulin. It binds to keratin in human cells, then once it reaches the fungal site of action, it binds to fungal microtubes thus altering the fungal process of mitosis.

# Melting_Point:
220 °C

# Molecular_Weight_Avg:
352.766

# Molecular_Weight_Mono:
352.071365983

# Organisms_Affected:
Yeast and other Trichophyton or Microsporum fungi

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/gri1190.shtml

# Pathways:
Not Available

# PharmGKB_ID:
PA449814

# Pharmacology:
Griseofulvin is a mycotoxic metabolic product of <i>Penicillium spp.</i> It was the first available oral agent for the treatment of dermatophytoses and has now been used for more than forty years. Griseofulvin is fungistatic with in vitro activity against various species of Microsporum Epidermophyton, and Trichophyton. It has no effect on bacteria or on other genera of fungi. Following oral administration, griseofulvin is deposited in the keratin precursor cells and has a greater affinity for diseased tissue. The drug is tightly bound to the new keratin which becomes highly resistant to fungal invasions. Once the keratin-Griseofulvin complex reaches the skin site of action, it binds to fungal microtubules (tubulin) thus altering fungal mitosis.

# Predicted_LogP_Hydrophobicity:
2.71

# Predicted_LogS:
-3.8

# Predicted_Water_Solubility:
5.04e-02 g/l

# Primary_Accession_No:
DB00400

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
441140

# PubChem_Substance_ID:
46508437

# RxList_Link:
http://www.rxlist.com/cgi/generic3/griseofulvin.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD01004

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
COC1=CC(OC)=C(Cl)C2=C1C(=O)[C@]1(O2)[C@H](C)CC(=O)C=C1OC

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Griseofulvina [INN-Spanish]
Griseofulvine [INN-French]
Griseofulvinum [INN-Latin]

# Synthesis_Reference:
Not Available

# Toxicity:
Side effects are minor: headaches, gastrointestinal reactions and cutaneous eruptions

# Update_Date:
2013-02-08 16:19:19 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Griseofulvin

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP1A2

# Phase_1_Metabolizing_Enzyme_1_ID:
4200

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 1A2

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 1A2
MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPLLGHVLTLGKN
PHLALSRMSQRYGDVLQIRIGSTPVLVLSRLDTIRQALVRQGDDFKGRPDLYTSTLITDG
QSLTFSTDSGPVWAARRRLAQNALNTFSIASDPASSSSCYLEEHVSKEAKALISRLQELM
AGPGHFDPYNQVVVSVANVIGAMCFGQHFPESSDEMLSLVKNTHEFVETASSGNPLDFFP
ILRYLPNPALQRFKAFNQRFLWFLQKTVQEHYQDFDKNSVRDITGALFKHSKKGPRASGN
LIPQEKIVNLVNDIFGAGFDTVTTAISWSLMYLVTKPEIQRKIQKELDTVIGRERRPRLS
DRPQLPYLEAFILETFRHSSFLPFTIPHSTTRDTTLNGFYIPKKCCVFVNQWQVNHDPEL
WEDPSEFRPERFLTADGTAINKPLSEKMMLFGMGKRRCIGEVLAKWEIFLFLAILLQQLE
FSVPPGVKVDLTPIYGLTMKHARCEHVQARRFSIN

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P05177

# Phase_1_Metabolizing_Enzyme_2_Gene_Name:
CYP3A4

# Phase_1_Metabolizing_Enzyme_2_ID:
4512

# Phase_1_Metabolizing_Enzyme_2_Name:
Cytochrome P450 3A4

# Phase_1_Metabolizing_Enzyme_2_Protein_Sequence:
>Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA

# Phase_1_Metabolizing_Enzyme_2_SwissProt_ID:
P08684

# Drug_Target_1_Cellular_Location:
Cytoplasmic

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
15105129	Kiso T, Fujita K, Ping X, Tanaka T, Taniguchi M: Screening for microtubule-disrupting antifungal agents by using a mitotic-arrest mutant of Aspergillus nidulans and novel action of phenylalanine derivatives accompanying tubulin loss. Antimicrob Agents Chemother. 2004 May;48(5):1739-48.
15280651	Wang L, Zhou HB, Frisvad JC, Samson RA: Penicillium persicinum, a new griseofulvin, chrysogine and roquefortine C producing species from Qinghai Province, China. Antonie Van Leeuwenhoek. 2004 Aug;86(2):173-9.
15868210	Czymmek KJ, Bourett TM, Shao Y, DeZwaan TM, Sweigard JA, Howard RJ: Live-cell imaging of tubulin in the filamentous fungus Magnaporthe grisea treated with anti-microtubule and anti-microfilament agents. Protoplasma. 2005 Apr;225(1-2):23-32. Epub 2005 May 4.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
M19398

# Drug_Target_1_GenBank_ID_Protein:
170938

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
TUB2

# Drug_Target_1_Gene_Sequence:
>1350 bp
ATGAGAGAAATTATTCATTTATCAACTGGTCAATGTGGTAATCAAATTGGTGCTGCCTTT
TGGGAAACTATTTGTGGAGAACATGGATTAGATAACAATGGAACTTATGTTGGAAATAAT
GAACTTCAAAAATCCAAATTAGACGTTTATTTCAACGAAGCTACTTCTGGGAAATACGTT
CCTCGTGCCGTTTTAGTCGATTTGGAACCAGGTACTATTGATAATGTGAAAACTTCACAA
ATTGGTAACTTGTTTAGACCAGATAACTTTATTTTCGGTCAAAGTTCTGCCGGCAATGTT
TGGGCTAAAGGTCATTACACTGAAGGTGCTGAATTAGTTGATTCTGTTTTAGATGTTGTT
AGAAGAGAAGCTGAAGGCTGTGATTCTTTACAAGGTTTCCAAATCACCCATTCTTTGGGT
GGTGGTACTGGTTCTGGTATGGGTACTTTGTTGATTTCTAAAATTAGAGAAGAATTCCCT
GATACAATGATGGCCACTTTTTCTGTTGTCCCATCACCAAAAGTTTCCGATACCGTTATT
GAACCATATAACGCTACTTTATCAGTCCATCAATTGGTTGAAAACTCTGATGAAACTTTC
TGTATTGATAATGAAGCCTTGTACAATATTTGTCAAAACACTTTGAAATTACCACAACCA
TCTTATGCTGAATTGAACAATTTGGTTTCTTCTGTCATGTCTGGTGTTACTACTTCTTTA
CGTTATCCAGGTCAATTGAATTCGGATTTAAGAAAATTGGCAGTCAATTTGGTTCCATTC
CCAAGATTACATTTCTTTATGGTTGGTTATGCTCCATTGACTTCTATGGGTTCTAAATCT
TTCAGATCAGTCACCGTCCCAGAATTGACTCAACAAATGTTTGATGCCAAAAATATGATG
GCTGCTTCTGATCCAAGAAATGGTCGTTATTTAACTGTTGCTGCCTTTTTCAGAGGTAAA
GTATCTGTTAAAGAAGTTGACGATGAAATGCACAAAATCCAAACCAGAAACTCATCTTAT
TTTGTTGATTGGATTCCAAATAATGTTCAAACTGCTGTTTGTTCAGTTCCTCCAAAAGAT
TTGGATATGTCTGCTACTTTTATTGGAAACTCTACTTCCATTCAAGAATTATTTAAAAGA
GTTGGTGATCAATTCAGTGCTATGTTCAGAAGAAAAGCTTTCTTGCATTGGTATACTTCT
GAAGGTATGGATGAAATGGAATTTACTGAAGCTGAATCTAATATGAATGATTTGGTTAGT
GAATACCAACAATACCAAGAAGCTAGTATTGATGAAGAAGAATTAGAATATGCCGATGAA
ATCCCATTAGAAGATGCCGCCATGGAATAA

# Drug_Target_1_General_Function:
Cell cycle control, cell division, chromosome partitioning

# Drug_Target_1_General_References:
3290053	Smith HA, Allaudeen HS, Whitman MH, Koltin Y, Gorman JA: Isolation and characterization of a beta-tubulin gene from Candida albicans. Gene. 1988;63(1):53-63.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
312

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
49942

# Drug_Target_1_Name:
Tubulin beta chain

# Drug_Target_1_Number_of_Residues:
449

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00091	Tubulin
PF03953	Tubulin_C

# Drug_Target_1_Protein_Sequence:
>Tubulin beta chain
MREIIHLSTGQCGNQIGAAFWETICGEHGLDNNGTYVGNNELQKSKLDVYFNEATSGKYV
PRAVLVDLEPGTIDNVKTSQIGNLFRPDNFIFGQSSAGNVWAKGHYTEGAELVDSVLDVV
RREAEGCDSLQGFQITHSLGGGTGSGMGTLLISKIREEFPDTMMATFSVVPSPKVSDTVI
EPYNATLSVHQLVENSDETFCIDNEALYNICQNTLKLPQPSYAELNNLVSSVMSGVTTSL
RYPGQLNSDLRKLAVNLVPFPRLHFFMVGYAPLTSMGSKSFRSVTVPELTQQMFDAKNMM
AASDPRNGRYLTVAAFFRGKVSVKEVDDEMHKIQTRNSSYFVDWIPNNVQTAVCSVPPKD
LDMSATFIGNSTSIQELFKRVGDQFSAMFRRKAFLHWYTSEGMDEMEFTEAESNMNDLVS
EYQQYQEASIDEEELEYADEIPLEDAAME

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha-chain

# Drug_Target_1_SwissProt_ID:
P10875

# Drug_Target_1_SwissProt_Name:
TBB_CANAL

# Drug_Target_1_Synonyms:
Beta tubulin

# Drug_Target_1_Theoretical_pI:
4.37

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Cytoplasmic

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
U38534

# Drug_Target_2_GenBank_ID_Protein:
2055378

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
TUB1

# Drug_Target_2_Gene_Sequence:
>1347 bp
ATGAGAGAAGTCATCAGTATTAATGTTGGTCAAGCCGGGTGTCAAATTGGTAACGCCTGT
TGGGAATTGTATTCACAGGAACATGGTATTAGACCAGATGGGTATTTACAAGAAGGTTTA
GACAGACCAAAGGGAGGAGAAGAAGGTTTTTCTACTTTTTTCAGTGAAACTGGTTCAGGT
AAATACGTTCCTCGTGCCTTGTATGTTGATTTGGAACCAAATGTCATTGATGAAGTTCGT
ACTGGTGTTTACAAAGATTTATTCCACCCTGAACAATTGATTGCCGGTAAAGAAGATGCC
GCCAATAATTATGCTAGAGGTCACTACACTGTTGGAAGAGAAATTTTAGACGACATTTTA
GATAGAGTCAGAAGAATGAGTGATCAATGTGACGGATTACAAGGTTTCCTTTTCACCCAC
TCTTTGGGTGGTGGTACCGGTTCCGGTTTGGGTTCTTTGTTATTGGAACAATTATCTTTG
GATTACGGTAAAAAATCCAAATTGGAATTTGCTGTTTACCCAGCTCCACAAGTGTCCACT
TCAGTTGTTGAACCATATAATACTGTGTTGACTACCCACACCACTTTGGAACACGCCGAT
TGTACTTTTATGGTTGATAATGAAGCCATCTACGATATGTGTAGAAGAAACTTGGATATT
GCCAGACCAAATTTTAGTTCATTGAACAACTTGATTGCTCAAGTTGTGTCATCCGTTACC
GCCTCTTTGAGATTTGACGGTTCCTTGAATGTTGATTTGAATGAATTCCAAACTAACTTG
GTTCCATACCCAAGAATCCATTTCCCATTGGTCAGTTATGCTCCAGTTTTCTCCAAGAGT
AGAGCTACCCATGAAGCCAACTCTGTTTCTGAAATTACTCAATCTTGTTTTGAACCAGGT
AACCAAATGGTCAAATGTGACCCAAGAACTGGTAAATACATGGCCACCTGTTTGTTATAC
CGTGGTGATGTTGTTACTAGAGACGTTCAAAATGCTGTTGCTCAAGTTAAATCTAAAAAG
ACTGTTCAATTAGTCGATTGGTGTCCAACTGGTTTCAAGATTGGTATCTGTTACCAACCA
CCAACTGCCATTAAGGGATCTGAATTGGCCAGTGCTTCTAGAGCTGTTTGTATGTTGTCT
AACACTACTGCCATTGCTGAAGCTTGGAGAAGAATTGACAGAAAATTCGACTTGATGTAC
TCTAAGAGAGCCTTTGTTCACTGGTACGTTGGTGAAGGTATGGAAGAAGGTGAATTCACT
GAAGCTAGAGAAGACTTGGCTGCTTTAGAGAGAGATTATATTGAAGTTGGTACTGATTCT
TTCCCTGAAGAAGAAGAAGAATATTAG

# Drug_Target_2_General_Function:
Involved in structural molecule activity

# Drug_Target_2_General_References:
9099874	Daly S, Yacoub A, Dundon W, Mastromei G, Islam K, Lorenzetti R: Isolation and characterization of a gene encoding alpha-tubulin from Candida albicans. Gene. 1997 Mar 18;187(2):151-8.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
712

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
49969

# Drug_Target_2_Name:
Tubulin alpha chain

# Drug_Target_2_Number_of_Residues:
448

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00091	Tubulin
PF03953	Tubulin_C

# Drug_Target_2_Protein_Sequence:
>Tubulin alpha chain
MREVISINVGQAGCQIGNACWELYSQEHGIRPDGYLQEGLDRPKGGEEGFSTFFSETGSG
KYVPRALYVDLEPNVIDEVRTGVYKDLFHPEQLIAGKEDAANNYARGHYTVGREILDDIL
DRVRRMSDQCDGLQGFLFTHSLGGGTGSGLGSLLLEQLSLDYGKKSKLEFAVYPAPQVST
SVVEPYNTVLTTHTTLEHADCTFMVDNEAIYDMCRRNLDIARPNFSSLNNLIAQVVSSVT
ASLRFDGSLNVDLNEFQTNLVPYPRIHFPLVSYAPVFSKSRATHEANSVSEITQSCFEPG
NQMVKCDPRTGKYMATCLLYRGDVVTRDVQNAVAQVKSKKTVQLVDWCPTGFKIGICYQP
PTAIKGSELASASRAVCMLSNTTAIAEAWRRIDRKFDLMYSKRAFVHWYVGEGMEEGEFT
EAREDLAALERDYIEVGTDSFPEEEEEY

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha-chain

# Drug_Target_2_SwissProt_ID:
P87066

# Drug_Target_2_SwissProt_Name:
TBA_CANAL

# Drug_Target_2_Synonyms:
Not Available

# Drug_Target_2_Theoretical_pI:
4.69

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Not Available

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
12388748	Nakamichi I, Hatakeyama S, Nakayama KI: Formation of Mallory body-like inclusions and cell death induced by deregulated expression of keratin 18. Mol Biol Cell. 2002 Oct;13(10):3441-51.
14693542	Sobue S, Sekiguchi K, Nabeshima T: Intracutaneous distributions of fluconazole, itraconazole, and griseofulvin in Guinea pigs and binding to human stratum corneum. Antimicrob Agents Chemother. 2004 Jan;48(1):216-23.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
Not Available

# Drug_Target_3_GenBank_ID_Protein:
Not Available

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
KRT12

# Drug_Target_3_Gene_Sequence:
Not Available

# Drug_Target_3_General_Function:
Not Available

# Drug_Target_3_General_References:
Not Available

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
7180

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
Not Available

# Drug_Target_3_Name:
Keratin, type I cytoskeletal 12

# Drug_Target_3_Number_of_Residues:
0

# Drug_Target_3_PDB_ID:
Not Available

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
Not Available

# Drug_Target_3_Protein_Sequence:
Not Available

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
Not Available

# Drug_Target_3_Specific_Function:
Not Available

# Drug_Target_3_SwissProt_ID:
Q99456

# Drug_Target_3_SwissProt_Name:
K1C12_HUMAN

# Drug_Target_3_Synonyms:
Not Available

# Drug_Target_3_Theoretical_pI:
Not Available

# Drug_Target_3_Transmembrane_Regions:
Not Available

#END_DRUGCARD DB00400
